MA41641A - Dérivés de tétrahydropyranylbenzamide - Google Patents

Dérivés de tétrahydropyranylbenzamide

Info

Publication number: MA41641A
Authority: MA; Morocco
Prior art keywords: tetrahydropyranylbenzamide; derivatives; tetrahydropyranylbenzamide derivatives
Prior art date: 2015-03-03

Application number

MA041641A

Other languages

English (en)

Inventor

zhi long Hu

Lian Zhu Liu

Tianwei Ma

Haizhen Zhang

Jingye Zhou

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-03

Filing date

2016-02-18

Publication date

2018-01-09

2016-02-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2018-01-09 Publication of MA41641A publication Critical patent/MA41641A/fr

Links

PYNBPZYZHMAOFS-UHFFFAOYSA-N O1C(CCCC1)C1=CC=CC=C1C(=O)N Chemical class O1C(CCCC1)C1=CC=CC=C1C(=O)N PYNBPZYZHMAOFS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrane Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA041641A 2015-03-03 2016-02-18 Dérivés de tétrahydropyranylbenzamide MA41641A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2015/073563 WO2016138631A1 (fr)	2015-03-03	2015-03-03	Composés imidazo benzamides

Publications (1)

Publication Number	Publication Date
MA41641A true MA41641A (fr)	2018-01-09

Family

ID=56849060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA041641A MA41641A (fr)	2015-03-03	2016-02-18	Dérivés de tétrahydropyranylbenzamide

Country Status (24)

Country	Link
US (1)	US10196385B2 (fr)
EP (1)	EP3265460A4 (fr)
JP (1)	JP2018507232A (fr)
KR (1)	KR20170106483A (fr)
CN (1)	CN107406436B (fr)
AU (1)	AU2016228055B2 (fr)
BR (1)	BR112017015448A2 (fr)
CA (1)	CA2975413A1 (fr)
CL (1)	CL2017002148A1 (fr)
CO (1)	CO2017008721A2 (fr)
CR (1)	CR20170354A (fr)
DO (1)	DOP2017000196A (fr)
EA (1)	EA201791745A1 (fr)
EC (1)	ECSP17058071A (fr)
IL (1)	IL253405A0 (fr)
MA (1)	MA41641A (fr)
MX (1)	MX2017011087A (fr)
PE (1)	PE20171650A1 (fr)
PH (1)	PH12017501560A1 (fr)
SG (1)	SG11201706718RA (fr)
SV (1)	SV2017005520A (fr)
TN (1)	TN2017000372A1 (fr)
WO (2)	WO2016138631A1 (fr)
ZA (1)	ZA201704948B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018014337A1 (fr) *	2016-07-22	2018-01-25	Eli Lilly And Company	3-chloro-n-[(1r18,3s)-3-[5-(3,5-diméthylimidazol-4-yl)-4h-1, 2, 4-triazol-3-yl]cyclohexyl]-n-méthyl-benzamide
MX2020009372A (es)	2018-03-09	2020-10-14	Recurium Ip Holdings Llc	1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2079728B1 (fr)	2006-10-10	2013-09-25	Amgen Inc.	Composés de n-arylpyrazole à utiliser contre le diabète
US8188098B2 (en)	2008-05-19	2012-05-29	Hoffmann-La Roche Inc.	GPR119 receptor agonists
US8653125B2 (en) *	2009-03-05	2014-02-18	Shionogi Co., Ltd.	Cyclohexane derivative having NPY Y5 receptor antagonism
WO2011088025A1 (fr) *	2010-01-15	2011-07-21	Merck Sharp & Dohme Corp.	Dérivés oxadiazole bêta-carboline comme composés antidiabétiques
US8822471B2 (en) *	2011-03-14	2014-09-02	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical compositions and uses thereof
WO2015120610A1 (fr)	2014-02-14	2015-08-20	Eli Lilly And Company	Composé agoniste de gpr142

2015
- 2015-03-03 WO PCT/CN2015/073563 patent/WO2016138631A1/fr not_active Ceased
2016
- 2016-02-18 MA MA041641A patent/MA41641A/fr unknown
- 2016-02-19 TN TNP/2017/000372A patent/TN2017000372A1/en unknown
- 2016-02-19 CN CN201680013049.8A patent/CN107406436B/zh active Active
- 2016-02-19 BR BR112017015448A patent/BR112017015448A2/pt not_active IP Right Cessation
- 2016-02-19 WO PCT/CN2016/074083 patent/WO2016138821A1/fr not_active Ceased
- 2016-02-19 SG SG11201706718RA patent/SG11201706718RA/en unknown
- 2016-02-19 EA EA201791745A patent/EA201791745A1/ru unknown
- 2016-02-19 EP EP16758437.4A patent/EP3265460A4/fr not_active Withdrawn
- 2016-02-19 MX MX2017011087A patent/MX2017011087A/es unknown
- 2016-02-19 KR KR1020177024303A patent/KR20170106483A/ko not_active Withdrawn
- 2016-02-19 PE PE2017001456A patent/PE20171650A1/es not_active Application Discontinuation
- 2016-02-19 CA CA2975413A patent/CA2975413A1/fr not_active Abandoned
- 2016-02-19 US US15/118,295 patent/US10196385B2/en active Active
- 2016-02-19 JP JP2017546161A patent/JP2018507232A/ja active Pending
- 2016-02-19 AU AU2016228055A patent/AU2016228055B2/en not_active Expired - Fee Related
- 2016-02-19 CR CR20170354A patent/CR20170354A/es unknown
2017
- 2017-07-10 IL IL253405A patent/IL253405A0/en unknown
- 2017-07-20 ZA ZA2017/04948A patent/ZA201704948B/en unknown
- 2017-08-21 DO DO2017000196A patent/DOP2017000196A/es unknown
- 2017-08-22 SV SV2017005520A patent/SV2017005520A/es unknown
- 2017-08-23 CL CL2017002148A patent/CL2017002148A1/es unknown
- 2017-08-28 CO CONC2017/0008721A patent/CO2017008721A2/es unknown
- 2017-08-30 PH PH12017501560A patent/PH12017501560A1/en unknown
- 2017-09-01 EC ECIEPI201758071A patent/ECSP17058071A/es unknown

Also Published As

Publication number	Publication date
PH12017501560A1 (en)	2018-02-05
CR20170354A (es)	2017-09-05
BR112017015448A2 (pt)	2018-01-30
CO2017008721A2 (es)	2018-01-05
DOP2017000196A (es)	2017-09-15
WO2016138631A1 (fr)	2016-09-09
JP2018507232A (ja)	2018-03-15
ECSP17058071A (es)	2017-10-31
EP3265460A4 (fr)	2018-08-08
ZA201704948B (en)	2019-02-27
CN107406436A (zh)	2017-11-28
WO2016138821A1 (fr)	2016-09-09
AU2016228055A1 (en)	2017-08-17
EP3265460A1 (fr)	2018-01-10
EA201791745A1 (ru)	2018-01-31
US20180194755A1 (en)	2018-07-12
KR20170106483A (ko)	2017-09-20
AU2016228055B2 (en)	2018-06-07
SG11201706718RA (en)	2017-09-28
SV2017005520A (es)	2018-08-27
US10196385B2 (en)	2019-02-05
CA2975413A1 (fr)	2016-09-09
CN107406436B (zh)	2021-02-26
MX2017011087A (es)	2017-11-10
PE20171650A1 (es)	2017-11-13
IL253405A0 (en)	2017-09-28
CL2017002148A1 (es)	2018-04-13
TN2017000372A1 (en)	2019-01-16

Publication	Publication Date	Title
FIC20230006I1 (fi)	2023-02-06	Vutrisiraani
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
DK3642202T3 (da)	2023-01-30	Dihydro-pyrrolo-pyridin-derivater
EP3280487A4 (fr)	2019-04-10	Estimation de distance électrode-nerf
PT3157915T (pt)	2019-05-16	Compostos de dihidroisoquinolinona substituídos
PT3298027T (pt)	2022-01-26	Compostos depsipéptidos antelmínticos
MA39822A (fr)	2018-02-06	Dérivés de pyrimidine bicycle
MA54254A (fr)	2021-09-22	Dérivés de benzodiazépine cytotoxique
DK3253762T3 (da)	2021-07-19	9h-pyrrolo-dipyridinderivater.
EP3457851A4 (fr)	2020-02-26	Dérivés de sobétirome
LT3402792T (lt)	2021-12-10	Chinolin-2-ono dariniai
EP3334726A4 (fr)	2019-04-17	Compositions de plinabuline
PT4039675T (pt)	2024-09-16	Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
LT3371168T (lt)	2020-10-12	Indolin-2-ono dariniai
EP3283171A4 (fr)	2019-03-13	Dérivés d'amphotéricine b
LT3464336T (lt)	2022-05-10	Junginiai
MA41790A (fr)	2021-06-02	Dérivé de morphinane
PT3131898T (pt)	2020-06-17	Derivados de fluoroalquilfluoreno
CL2016002165A1 (es)	2017-06-09	Compuestos de aminocarbonilcarbamato
EP3309163A4 (fr)	2019-01-09	Dérivé de dihydropyrrolopyrazole substitué
LT3362444T (lt)	2021-06-25	Junginiai
DK3597189T3 (da)	2022-06-27	Krystallinske forbindelser
EP3333163A4 (fr)	2019-01-09	Dérivé de guanidine substitué
EP3308781A4 (fr)	2019-01-23	Agent hypotenseur
EP3554637A4 (fr)	2020-05-20	Dérivés de spiropipéridine